News

Two patients with late infantile GM1 gangliosidosis in Cohort 1 received a low dose of the treatment, reporting no serious adverse events. Passage Bio noted it plans to move forward with 2 additional cohorts.

These news stories dominated the conversations in the field and were often included in NeurologyLive®'s coverage in Alzheimer disease and dementia.

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided insight on a new study that looks at the connection between brain structure and cognitive decline in patients with multiple sclerosis and other neurodegenerative disorders.

The research assistant professor at the Buffalo Neuroimaging Analysis Center discussed a recently awarded grant to determine which brain structures are responsible for cognitive decline in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

The study had a relatively high proportion of Black and Hispanic participants, with higher MCI among these patients.

The FDA has placed the investigational new drug application for the treatment on clinical hold.

The director of the Joseph Epstein Center for Emergency Medicine Research discussed why guidelines developed by international bodies would provide crucial direction for emergency departments in how they treat presenting headache. [WATCH TIME: 3 minutes]

As Dravet syndrome is often nonresponsive to existing therapeutics, it can be a challenge to treat, and this refractory nature creates a great need for novel, innovative, and safe antiepileptic drugs for its treatment.

Although similar in reducing the risk of recurrent stroke, the use dual antiplatelet therapy with clopidogrel and aspirin was associated with a decreased risk of functional disability compared with ticagrelor and aspirin.

The treatment was well-tolerated in children with AS, positively affecting constipation, a common symptom of the condition.

The diagnosis of Parkinson disease may seem straightforward at first, requiring neurologists to rely on their eyes and hands, but the treatment process can present challenges for both physicians and patients.

Although the new integrated cognitive assessment can be completed remotely, the chief medical officer of Cognetivity outlined its potential for use in the clinical setting.

After months of concern raised by the Alzheimer disease community about the list price for aducanumab (Aduhelm) of $56,000 yearly, Biogen has announced that the maintenance dose cost will be reduced to $28,200.

Here's what is coming soon to NeurologyLive®.

The phase 4 study will enroll 300 patients with amyotrophic lateral sclerosis who have started treatment with edaravone (Radicava; Mitsubishi Tanabe Pharma America).

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, provided context on improving our use of current antiseizure medications as the top priority for patients with epilepsy. [WATCH TIME: 2 minutes]

These findings have clinical implications for the diagnosis of AQP4-NMOSD and in helping clinicians differentiating it from other demyelinating diseases such as MOGAD.

The newly awarded programs complement AC Immune’s portfolio in PD, which includes an anti-α-syn vaccine, next generation PET imaging tracer, and a preclinical stage anti-α-syn antibody.

Amy Kunchok, MD, staff neurologist at the Mellen Center for Multiple Sclerosis and Research at Cleveland Clinic, discussed a recent talk she gave that highlighted the different phenotypes of AQP-IgG NMOSD and MOGAD.

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

Argenx’s antibody fragment to target the neonatal Fc receptor is the first in its class, with its approval backed by data from the phase 3 ADAPT trial.

Pharma Two B anticipates filing a new drug application to the FDA for the investigational treatment in 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

The chief medical officer of Cognetivity outlined a new integrated cognitive assessment that takes only 5 minutes to complete on an iPad. [WATCH TIME: 6 minutes]

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Anton Porsteinsson, MD.

Two parallel studies will evaluate the BioXcel Therapeutics’ drug’s effectiveness as an acute therapy in treating a full spectrum of agitation in 300 patients with AD.

Findings represent the most comprehensive metabolic profiling of this patient population as a function of body mass index.

The staff neurologist at the Cleveland Clinic Mellen Center for Multiple Sclerosis outlined key findings from her talk at a recent Institutional Perspectives in Neurology: Multiple Sclerosis event. [WATCH TIME: 3 minutes]

The post-marketing study of aducanumab (Aduhelm) is expected to enroll 1300 patients with early Alzheimer, with the final protocol to be submitted to the FDA in March 2022, and plans to initiate patient screening in May 2022.